world-class Discovery
Chemistry services
20+ years
of legacy
Integrated Chemistry and Biology solution at every stage of drug discovery
State-of-the-art
infrastructuren
Our small molecule discovery services offerings
Aurigene offer diverse solutions to all your medicinal chemistry research requirements, providing the right blend of innovation, vigour, expertise and thorough knowledge of the various aspects of discovery research. With a very experienced scientific team with a 1:6 PhD to MSc ratio and a leadership team with a collective experience of >200 years, together with our experience in handling complex synthetic chemistry problems and our in-house collection of >50000 chemicals,
we are ready to rapidly initiate any chemistry programs from our collaborators. We are well versed in all aspects of medicinal chemistry projects, including novel areas like carbohydrates and steroids, PROTACs and molecular glues, oligonucleotides etc.
With a combination of 600+ highly skilled scientists and a state-of-the-art infrastructure spanned over two sites at Bangalore and Hyderabad, we provide the best-in-class medicinal chemistry services to various biotech, pharmaceutical and agrochemical companies. We offer flexible business models like FFS in addition to the usual FTE mode of collaboration, in addition to offering a variety of mix and match programs like chemistry CRO programs together with DMPK or in vitro Biology programs
We provide analytical services for NCEs, APIs and formulation of DS and DP. We are well equipped with high-end instruments for purification like Mass Directed Purification (MDD) and Supercritical Fluid Chromatography (SFC). We also facilitate impurity identification, characterization and isolation. We provide end-to-end support for analytical services. The state-of-the-art infrastructure at our R and D centers is well-equipped with the latest analytical instruments that enable us to provide high-quality, cost-effective services for our customers
We have the capability for designing and executing mid-size libraries in a remarkably shorter time frame, helping in quick screening for desired properties. Our large and selective in-house collection of acids, aldehydes, amines, phenols, boronic acids and heterocyclic halides are carefully selected to be compatible with most of the drug discovery concepts. We have capacity and experience to generate structurally diverse scaffolds in gram scale and to carry out their rapid diversifications using 1-3 step transformations with reactions like amide couplings, mitsunobu reactions, transition metal-mediated C-C and C-N bond-forming reactions, reductive aminations, click Chemistry etc
At Aurigene Pharmaceutical Services, we design strategic approaches to improve druggability by improving bioavailability and ADME parameters. We provide end-to-end solutions from discovery to manufacturing.
Our portfolio of peptides ranges from simple side-chain modification upto 80 amino acids to backbone and side-chain modified peptides and derivatized peptides.
PROteolysis – TArgeting Chimeras (PROTACs) are a series of hetero-bifunctional molecules that hijack the body’s own natural disposal system to initiate selective degradation of the protein of interest (POI). PROTACs have the potential to overcome most of the limitations of small molecule inhibitors, and they offer several advantages of the traditional concepts of drug discovery. Aurigene offers expertise in the synthesis of PROTACs and partial PROTACs for targeted
protein degradation & integrated drug discovery even on the multi-gram scale. We have extensive experience in not only the synthesis and purification of PROTACs, but also the capability of extensively profiling our synthesized PROTACs including various Biological assays, DMPK and Toxicology support. We are uniquely poised in the Indian CRO market not only as a key player with extensive knowledge in small molecule-based Drug Discovery research, but also can offer our significant experience on the PROTAC-related domain to any potential collaborators.
We are well versed in the synthesis and functionalization of various E3-ligase ligands such as CRBN, VHL, MDM2, and cIAP1 (in multi-gram scale) and in the synthesis of commercially available ligands, as well as in developing novel structural analogues as per custom requests. We also have significant experience in the niche fields of Targeted Protein Degradation (TPD) like molecular glues and ATTECs.
The oligonucleotide synthesis services at Aurigene is supported by a state-of-the-art lab facility and skilled scientists with expertise in various types of oligos. We have an in-house custom synthesis of phosphoramidites and the ability to perform complex conjugation using click chemistry, amide coupling and thiol mediated C-S & S-S bond.
Our dedicated lab space of 1000 sq.ft is equipped with humidity control. Aurigene’s oligonucleotide platform
is supported by trained team that helps optimize the designed oligonucleotide along with primary assay iterations. We have the ability to synthesize 10-40-mer oligonucleotide up to 1-gram scale. We perform all standard modifications, with or without backbone modification, for which phosphoramidites are made in-house and also available commercially.
Oligo equipments at Aurigene:
- K and A H-16 automated DNA/RNA synthesizer
- AKTA pure 25M FPLC purification system
- Sartoflow smart TFF system for concentration and desalting
- Martin Christ LSC plus lyophilizer with lyocube, benchtop tray lyophilizer
- Agilent LC-MS for oligonucleotide analysis
- Implen N60 nano spectrophotomete
The services at Aurigene enable clients to have quick access to building blocks, intermediates, and final drug substances from gram-scale to multi-kilo-scale. The team comprises of analytical, process development scientists and engineers having expertise in small-scale synthesis to large-scale manufacturing. The accelerated delivery of pre-clinical candidates to the customer expectation is driven by phase appropriate development approach.
Our Services
- Target hit identification
- Route scouting
- Phase appropriate development
- Standalone FFS target deliveries
We have 3 kilo lab facilities for scale-up
- Hyderabad- 20 and 50 L
- Bangalore- 5, 10, 20, 50 L
- Hyderabad, Potent lab- 20 and 50 L
We offer technical services in various segments
- FTE and FFS projects
- Target Synthesis
- Process R and D Peptides Oligonucleotides Lipids Tox and pre-clinical studies
Why Aurigene CRDMO services?
25+ years of expertise & quality track record
- Commercialized 6 products in 30+ countries
- 200+ scientists
- Accredited & certified facilities - USA FDA, EMA inspected CGMP facility, & AAALAC accredited vivarium
State-of-the art facilities
- Pilot/clinical scale facility for CGMP & non-GMP supplies (200L reactors)
- Large scale commercial CGMP Drug Substance facility with single use bioreactors with capacity of ~25,000 L
- CGMP Drug Product filling vials, pre-filled syringes and cartridge or device for liquid and lyophilized formulations
Our Infrastructure
R and D centers
Aurigene Pharmaceutical Services is well-equipped with laboratories from discovery to clinical phase III for NCEs and NBEs. We operate two state-of-the-art R and D centers in Bangalore and Hyderabad. Our R and D centers are equipped with 60+ modular laboratories to handle highly potent substances, peptides, oligonucleotides etc. Our facility also has an extensive analytical center of excellence in addition to special purpose labs for safety assessment studies and polymorphism studies. Our best-in-class discovery biology services are supported by AAALAC accredited vivarium, BSL-2 compliant labs, in vivo facilities, GLP and other regulatory bodies accredited toxicology labs. Our state-of-the-art preclinical evaluation safety facility has been inspected by FCPSA Netherlands, DCGI and is annually inspected by National GLP Compliance Monitoring Authority (NGCMA). Our facility has also been inspected by the US FDA and the quality systems in this facility are in accordance with NGCMA and US FDA standards.
Manufacturing facilities
We have access to cGMP manufacturing facilities in the UK, Mexico and India. We operate thousands of kilo liters of API capacities that can handle various range of chemistries from regular small molecules, peptides, potent compounds, steroids, carbohydrates and pegylated drugs. In addition, we also operate formulation manufacturing plants that can handle various dosage forms including oral solids, parenteral and topical. Our facilities are designed modularly and offer flexibility of scale, enabling efficient operations. Our manufacturing facilities are regularly inspected by regulatory agencies.
ESG/Sustainability
Aurigene as a wholly owned subsidiary of Dr. Reddy’s Laboratories adopts the ESG goals of our parent company. Dr.Reddy’s has been committed to sustainability, diversity and equality for over two decades and has been honored with numerous accreditations and awards.
Awarded ‘Gold Medal’ status by EcoVadis, the global sustainability ratings agency, 2023
First Indian pharma firm to earn a place in the Standard & Poor Dow Jones Sustainability World Index (DJSI World) for 2023.
6th year in a row to be featured in the Bloomberg Gender-Equality Index (GEI) 2023.
Achieved “A” rating for supplier engagement, and for climate change & water security in 2023 by Carbon Disclosure Project (CDP)
The Aurigene expertise
Your trusted CRO/CDMO partner for end-to-end services across drug discovery, development, and manufacturing.
With a legacy of 25 years, Aurigene offers integrated and standalone services in drug discovery space for chemistry and biology to innovative pharma and biotech companies. As per customer needs, we are flexible in our approach and offer a variety of business models, including FTE and FFS modes of collaboration, integrated projects, stand-alone chemistry or biology projects, and mix-and-match programs. Our track record and experience in discovery services have helped our clients accelerate their drug discovery programs. Our highly qualified and experienced team of scientists is supported by state-of-the-art infrastructure in Bangalore and Hyderabad to help advance our client molecules through the different phases of pre-clinical discovery (i.e., target identification to hit, hit to lead, lead optimization, and pre-clinical stage).
Explore how we accelerate small molecules' journey from target
to candidate with end-to-end discovery services.
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market